drugset / Trial / NCT00255346
Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The goal of this clinical research study is to learn if dasatinib can help to control myeloproliferative disorders. The safety and tolerability of dasatinib will also be studied.
Timeline
- Start
- 2005-11-15
- Primary completion
- 2017-03-03
- Completion
- 2017-03-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | dasatinib anhydrous | Small molecule | 70 mg | Oral |